Page last updated: 2024-10-26

dilazep and Androgen-Independent Prostatic Cancer

dilazep has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kaochar, S1
Rusin, A1
Foley, C1
Rajapakshe, K1
Robertson, M1
Skapura, D1
Mason, C1
Berman De Ruiz, K1
Tyryshkin, AM1
Deng, J1
Shin, JN1
Fiskus, W1
Dong, J1
Huang, S1
Navone, NM1
Davis, CM1
Ehli, EA1
Coarfa, C1
Mitsiades, N1

Other Studies

1 other study available for dilazep and Androgen-Independent Prostatic Cancer

ArticleYear
Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
    Endocrine-related cancer, 2021, 11-24, Volume: 29, Issue:1

    Topics: Cell Line, Tumor; Chromatin; Dilazep; GATA2 Transcription Factor; Gene Expression Regulation, Neopla

2021